18.49 USD
▼-1.06-5.42%
盘后 18.71 +1.19%
2026-10-16
市值
$1.53B
市盈率
—
EPS
-14.69
股息率
—
52 周区间
17.86 – 32.00
成交量
414.85K
Beta
—
目标价
45.25
52W 低 17.8652W 高 32.00
价格走势
公司简介
Braveheart Bio, Inc. a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. It develops and offers BHB-1893 and HRS-1893, an oral small-molecule cardiac myosin inhibitor (CMI) for the treatment of obstructive HCM and non-obstructive HCM. The company was incorporated in 2024 and is headquartered in San Francisco, California.